The past year for Ligia Pinto, Ph.D., and her staff has been full of pressure and remote meetings at all hours of the day and night. It’s also been one of partnerships and progress. Pinto heads the Vaccine, Immunity, and Cancer Directorate, the group at the Frederick National Laboratory that’s leading the national SARS-CoV-2 Serological Sciences Network (SeroNet). At this time last year, her laboratories, which specialized in human papillomavirus, antibody science, and serology, had just been asked to help the Food and Drug Administration evaluate the quality of the new SARS-CoV-2 antibody tests that were flooding the market.